Company news
Emvision Medical Devices Ltd. (ASX:EMV) news
Emvision Medical Devices Ltd. news releases on 6ix. Latest, Sep 27, 2026: $4.3m Non-Dilutive R&D Tax Rebate Received
Press releases & updates
$4.3m Non-Dilutive R&D Tax Rebate Received
September 27, 2026
First Responder Successfully Trialled with MSU
September 15, 2026
emu Regional Benefits Study Advancing
September 2, 2026
emu Pivotal Trial Recruitment Surpasses 200 Patients
August 30, 2026
Appendix 4E & Annual Report to 30 June 2026
August 23, 2026
Aeromedical Study De-Risks Rural & Remote Stroke Use Cases
May 26, 2026
EMVision to Receive $1.17M IGP Grant Instalment
May 24, 2026
emu Pivotal Trial Expansion Adds Acute Ischaemia Detection
May 10, 2026
$3.8m R&D Rebate Received & Overseas Finding Approved
March 15, 2026
Update - S&P DJI March 2026 Rebalance of the All Ordinaries
March 10, 2026
S&P DJI Announces March 2026 Quarterly Rebalance
March 6, 2026
EMVision Medical Devices to Present at Australia Investor Day February 26th
February 24, 2026
Half Yearly Report and Accounts
February 22, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 27, 2026
Strong emu Clinical Trial & Program Progress
January 26, 2026
First Responder Aeromedical Study Commences
November 26, 2025
Oversubscribed SPP Raises $2.0M
October 31, 2025
Oversubscribed SPP To Close Early
October 21, 2025
$3m CRC-P Grant Executed & First Payment Received
October 13, 2025
SPP Offer Document & Option Prospectus
September 28, 2025
Pre-Hospital MSU Study Commences with First Responder Device
September 23, 2025
Firm Commitments for $12.0M Placement & Launch of SPP
September 16, 2025
Trading Halt
September 15, 2025
Appendix 4E & Annual Report to 30 June 2025
August 27, 2025
UCLA Health Activation & Continuous Innovation Study Update
August 25, 2025
EMVision Awarded $3m Grant For Regional Benefits Study
August 14, 2025
First Responder Program Advanced & Grant Milestone Achieved
July 28, 2025
Key Developments in Pivotal Trial & Innovation Study
July 1, 2025
EMVision Awarded $5m Non-Dilutive Government Grant
June 15, 2025
Additional Pivotal Trial Site Activations
June 2, 2025
Enhanced Algorithm Performance From Continuous Innovation
May 20, 2025
Activation of Second US Pivotal Trial Site, Mayo Clinic
April 27, 2025
Emu Pivotal Validation Trial Commences
March 26, 2025
First Responder Scanner in Successful Aeromedical Testing
March 18, 2025
S&P DJI Announces March 2025 Quarterly Rebalance
March 7, 2025
EMVision Releases its FY25 Half Yearly Report
February 27, 2025
US Ethics Approval Received for Pivotal Validation Trial
February 11, 2025
EMVision Receives $2.12m R&D Tax Rebate
January 19, 2025
Algorithms Deliver Excellent Results In EMView Study
November 11, 2024
EMV Prepares for Trial Following Positive FDA Engagement
October 28, 2024
Appendix 4E & Annual Report to 30 June 2024
August 27, 2024
First Responder Device Unveiled
July 22, 2024
Stage 3 Recuitment Achieved & FDA Engagement Underway
July 7, 2024
Pilot Production Line Established & $1.25m Grant Received
June 23, 2024
Trial data confirms early ischaemia detection capabilities
May 26, 2024
Stage 2 Insights Confirm Diagnostic & Clinical Viability
March 26, 2024
ASA Milestone Achieved for $0.6m Grant Payment
March 12, 2024
Strategic A$15.28M Investment from Keysight Technologies
February 28, 2024
EMVision Receives $2.58m R&D Rebate & ASA Milestone Achieved
December 17, 2023
Stage 2 Trial Recruitment Tartget Reached & EMU Unveiled
November 26, 2023